Clinical trials: Renal and Urinary Disorders
Bladder Cancers
Detection of Chromosomal Aberrations in Urine Samples Using Fluorescent in Situ Hybridization (FISH) (UroVysion Test)
The purpose of the study is the identification of chromosomal aberrations in urine samples. The imaging system is intended for diagnostic use as an aid to the pathologist in the detection, counting and classification of UroVysion…
- Trial name
- NCT01264744
- Where
- 3 sites in United States
- Volunteers
- 174 people
- Sponsor
- Applied Spectral Imaging Ltd.
Renal Insufficiency
Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney Disease
The objective of this long term study is to prospectively compare the incidence of NSF in two cohorts (Cohort 1- patients with moderate chronic kidney disease eGFR 30-59 and Cohort 2- patients with severe chronic kidney disease…
- Trial name
- NCT00600834
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Bracco Diagnostics, Inc
End Stage Renal Disease, Hemodialysis Access Failure
PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis
The goal of this observational study is to increase the understanding of the safety and performance of Merit Medical's HeRO Graft System (HeRO) and Super HeRO Adaptor and Support Seal System (Super HeRO) devices.
- Trial name
- PReSeRVE-HD (NCT06422871)
- Testing
- HeRO® Graft System or Super HeRO® System
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- Merit Medical Systems, Inc.
Chronic Kidney Disease
Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing
A randomized, cross-over, open-label study will be conducted to evaluate the equivalency, safety and tolerability of sevelamer once per day dosing, given with the largest meal, compared with standard three times per day dosing…
- Trial name
- NCT00324376
- Testing
- Sevelamer hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genzyme, a Sanofi Company
Urinary Incontinence, Urinary Obstruction
NXT Post-Market Clinical Follow-up
NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation to Confirm Ongoing Safety and Performance in Urodynamic Patient Sub-Populations
- Conditions
- Urinary Incontinence, Urinary Obstruction, Urinary Bladder, Overactive, Urinary Bladder, Neurogenic
- Trial name
- NCT06336304
- Testing
- Urodynamic procedure
- Where
- 5 sites in United States
- Volunteers
- 163 people
- Sponsor
- Laborie Medical Technologies Inc.
Chronic Kidney Disease
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes…
- Trial name
- NCT06717698
- Testing
- NNC0519-0130, Semaglutide
- Where
- 147 sites in United States, Argentina and 12 more
- Volunteers
- 465 people
- Sponsor
- Novo Nordisk A/S
Urologic Neoplasms
Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy
The purpose of this trial is to assess the anti-tumour activity and safety of afatinib monotherapy in patients with urothelial tract carcinoma carrying ERBB2 or ERBB3 (Erythroblastic leukaemia viral oncogene homolog of the human…
- Trial name
- LUX-Bladder 1 (NCT02780687)
- Testing
- Afatinib
- Where
- 30 sites in France, Italy and 1 more
- Volunteers
- 42 people
- Sponsor
- Boehringer Ingelheim
Hyperkalaemia, Chronic Kidney Disease
Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study
This is an open-label, randomised study in participants with chronic kidney disease (CKD) treated for hyperkalaemia (HK) whilst in hospital.
- Trial name
- CONTINUITY (NCT05347693)
- Testing
- Sodium Zirconium Cyclosilicate (SZC), Local standard of care
- Where
- 28 sites in Belgium, France and 4 more
- Volunteers
- 186 people
- Sponsor
- AstraZeneca
Kidney Cancer
RPI.4610 in Treating Patients With Metastatic Kidney Cancer
RATIONALE: RPI.4610 may stop the growth of metastatic kidney cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of RPI.4610 in treating patients who have metastatic kidney cancer.
- Trial name
- NCT00021021
- Testing
- anti-FLT-1 ribozyme
- Where
- United States
- Sponsor
- Ribozyome
IgA Nephropathy, Immunoglobulin A Nephropathy
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
The ASSIST study was a phase 2, double-blind, placebo-controlled crossover study to evaluate the safety and efficacy of atrasentan vs.
- Trial name
- ASSIST (NCT05834738)
- Testing
- Atrasentan
- Where
- 30 sites in United States, Australia and 4 more
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Nephropathy, Type 2 Diabetes Mellitus
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
The purpose of this study is to evaluate the safety and efficacy of treatment with CCX140-B in subjects with diabetic nephropathy.
- Trial name
- NCT01447147
- Testing
- CCX140-B
- Where
- 83 sites in Belgium, Czechia and 4 more
- Volunteers
- 332 people
- Sponsor
- Amgen
Non-muscle-invasive Bladder Cancer
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.
- Trial name
- NCT05710848
- Testing
- STM-416
- Where
- 20 sites in United States
- Volunteers
- 75 people
- Sponsor
- SURGE Therapeutics
Renal Failure
Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily
This is 2-armed parallel group, prospective, randomized, open-label, multicenter Phase 3 controlled trial to establish the efficacy and safety of conversion from maintenance immunosuppressive therapy with Prograf® capsules…
- Trial name
- NCT00817206
- Testing
- LCP-Tacro, Prograf
- Where
- United States
- Volunteers
- 326 people
- Sponsor
- Veloxis Pharmaceuticals
Alport Syndrome
A Study of ELX-02 in Patients With Alport Syndrome
This is a Phase 2 open label pilot study to evaluate the safety and efficacy of subcutaneously administered ELX-02 in patients with X-linked or autosomal recessive Alport Syndrome with Col4A5 and Col4A3/4 nonsense mutation.
- Trial name
- NCT05448755
- Testing
- ELX-02
- Where
- 4 sites in Australia, United Kingdom
- Volunteers
- 3 people
- Sponsor
- Eloxx Pharmaceuticals, Inc.
Chronic Renal Insufficiency, End-Stage Renal Disease
A Study in Children With Growth Failure Due to Chronic Renal Insufficiency (CRI) or End Stage Renal Disease (ESRD)
This study is a multicenter, open-label, observational, postmarketing surveillance study that will collect information on the use of Genentech growth hormone (GH) preparations to treat children with CRI in the United States.
- Trial name
- NCT00097617
- Volunteers
- 395 people
- Sponsor
- Genentech, Inc.
Urinary Bladder, Overactive
A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.
The drug being studied, fesoterodine fumarate helps prevent the bladder neck opening at unwanted times and has been shown to help patients with overactive bladder syndrome pass urine less frequently than before treatment.
- Trial name
- SOFIA (NCT00798434)
- Testing
- Fesoterodine fumarate
- Where
- 60 sites in Austria, Belgium and 13 more
- Volunteers
- 794 people
- Sponsor
- Pfizer
Overactive Bladder
Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the Package Insert (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance…
- Trial name
- POTTOR (NCT01488578)
- Testing
- Tolterodine tartrate
- Volunteers
- 11,157 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Proteinuria
An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))
The purpose of this study is to evaluate the effects of losartan on proteinuria in pediatric patients.
- Trial name
- NCT00568178
- Testing
- Losartan Potassium, Comparator: amlodipine besylate
- Volunteers
- 306 people
- Sponsor
- Organon and Co
Kidney Disease, Chronic Kidney Disease
Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis
The purpose of this study is to evaluate the efficacy and safety of cinacalcet compared with placebo in patients with stage 3 and 4 Chronic Kidney Disease (CKD).
- Trial name
- NCT00094484
- Testing
- Cinacalcet HCl
- Volunteers
- 400 people
- Sponsor
- Amgen
Cardiac Surgery, Coronary Artery Bypass Grafting
Pharmacokinetics of AP214 Acetate in Patients Undergoing Cardiac Surgery
The purpose of the present research study is to investigate the pharmacokinetics, as well as safety, tolerability and pharmacodynamics of different ascending dosing regimens of AP214 in patients undergoing cardiac surgery.
- Conditions
- Cardiac Surgery, Coronary Artery Bypass Grafting, Valve Surgery, Aortic Root or Ascending Aortic Aneurysm Repair Surgery
- Trial name
- NCT00903604
- Testing
- AP214
- Where
- 2 sites in Denmark
- Volunteers
- 42 people
- Sponsor
- Action Pharma A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.